T cells early after neoadjuvant triple immunotherapy. Our results suggest that the addition of IL-2 can overcome resistance to neoadjuvant anti-CTLA4 + anti-PD1, providing the rationale for testing this combination as a neoadjuvant therapy in patients with early-stage cancer.
| Authors | Kaptein, Paulien; Jacoberger-Foissac, Celia; Dimitriadis, Petros; Voabil, Paula; de Bruijn, Marjolein; Brokamp, Simone; Reijers, Irene; Versluis, Judith; Nallan, Gahyathiri; Triscott, Hannah; McDonald, Elizabeth; Tay, Joshua; Long, Georgina V; Blank, Christian U; Thommen, Daniela S; Teng, Michele W L |
|---|---|
| Journal | Science Translational Medicine |
| Pages | eabj9779 |
| Volume | 14 |
| Date | 1/01/2022 |
| Grant ID | |
| Funding Body | |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1126/scitranslmed.abj9779 |